REALM-DCM: a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 (PF-07265803) in patients with symptomatic LMNA-related dilated cardiomyopathy

20 May 2023 (13:00 - 13:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Roberto Barriales-Villa

Coruna University Hospital Complex, Coruna, A (Spain)

5 More presentations in this session

Presentation thumbnail

Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series

Doctor J. Brito (Lisbon, PT)

Abstract Slides

Presentation thumbnail

Trace element equilibrium in acute heart failure and the effect of empagliflozin

Assistant Professor N. Bomer (Groningen, NL)

Abstract Slides

Presentation thumbnail

Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.

Doctor R. Rascon Sabido (Veracruz, MX)

Abstract Slides

Presentation thumbnail

Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction

Doctor J. Youn (Seoul, KR)

Abstract Slides

Presentation thumbnail

Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction

Doctor M. Amiguet Comins (Castellon de la Plana, ES)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - pharmacotherapy 5

The Event

Event poster

Heart Failure 2023

20 May 2023 13:00 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources